Last week, you might have seen that Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SZSE:002223) released its first-quarter result to the market. The early response was not positive, with shares down 2.8% to CN¥33.98 in the past week. Results look mixed - while revenue fell marginally short of analyst estimates at CN¥2.2b, statutory earnings were in line with expectations, at CN¥2.41 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

After the latest results, the eleven analysts covering Jiangsu Yuyue Medical Equipment & Supply are now predicting revenues of CN¥8.47b in 2024. If met, this would reflect a decent 15% improvement in revenue compared to the last 12 months. Per-share earnings are expected to jump 23% to CN¥2.14. Before this earnings report, the analysts had been forecasting revenues of CN¥8.54b and earnings per share (EPS) of CN¥2.18 in 2024. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

The analysts reconfirmed their price target of CN¥46.49, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Jiangsu Yuyue Medical Equipment & Supply, with the most bullish analyst valuing it at CN¥49.69 and the most bearish at CN¥44.00 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Jiangsu Yuyue Medical Equipment & Supply's rate of growth is expected to accelerate meaningfully, with the forecast 21% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 9.0% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 19% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Jiangsu Yuyue Medical Equipment & Supply is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at CN¥46.49, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Jiangsu Yuyue Medical Equipment & Supply going out to 2026, and you can see them free on our platform here.

Even so, be aware that Jiangsu Yuyue Medical Equipment & Supply is showing 1 warning sign in our investment analysis , you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.